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Abstract The microtubule-associated protein tau favors micro-
tubule nucleation and stabilization and plays a role in the
elongation of axons. We have investigated the ability of glycogen
synthase kinase-3L (GSK-3L) to control tau-induced processes
outgrowth. Tau-transfected Chinese hamster ovary (CHO) cells
developed processes containing microtubule bundles after cyto-
chalasin treatment, but a significant reduction in the number of
cells harboring processes was observed in tau/GSK-3L-co-
transfected cells. Lithium, an inhibitor of GSK-3L, counteracted
in a dose-dependent manner this inhibitory effect of GSK-3L.
These findings suggest that GSK-3L modulates in a graded
manner the ability of tau to control the microtubule-dependent
induction of cell processes.
z 2000 Federation of European Biochemical Societies.
Key words: Tau; Glycogen synthase kinase-3L ; Microtubule;
Cell process; Phosphorylation; Lithium
1. Introduction
Tau proteins are microtubule-associated proteins, abundant
in neurons, that modulate several aspects of microtubule be-
havior: they favor the nucleation of new microtubules, reduce
their dynamic instability, induce a bundling of microtubules in
transfected cells and stabilize microtubules against depolyme-
rizing agents (for review, see [1]). The expression of tau in
some transfected cells [2,3] and in insect Sf9 cells with a ba-
culoviral vector [4] induces the formation of cell processes
containing bundles of ordered microtubules. This property
might be related to a role for tau in establishing an axonal
morphology: for instance, the development of axons of cul-
tured neurons is inhibited by treatment with tau anti-sense
oligonucleotides [5].
The control of cell processes outgrowth also requires intra-
cellular signaling mechanisms that act on cytoskeletal pro-
teins, such as the control of the phosphorylation of MAPs.
For instance, highly phosphorylated tau proteins are less e⁄-
cient in their ability to promote microtubule assembly. Tau is
a substrate for many protein kinases in cell-free systems, but
less data are available on kinases regulating tau function in
cells. Glycogen synthase kinase-3L (GSK-3L), a kinase abun-
dant in brain [6] and widely distributed in neurons in vivo [7],
is a candidate physiological kinase for tau phosphorylating
tau in transfected cells [8], in cultured neurons [9^11] and in
the rat brain [9]. To investigate the ability of GSK-3L to
control tau function in a cellular system, we have studied
the consequence of GSK-3L expression on tau-dependent
processes formation. We have found that the gradual inhib-
ition of GSK-3L results in a graded e¡ect on process growth,
demonstrating that changes in GSK-3L activity could be a
mechanism for subtle changes in processes properties.
2. Materials and methods
2.1. Cell transfection and experimental treatments
Chinese hamster ovary (CHO) cells were routinely cultured in
HAM F12 medium supplemented with 10% fetal bovine serum,
100 IU penicillin and 100 Wg/ml streptomycin. CHO cells were trans-
fected using lipofectamine (Gibco BRL) with a tau (one N-terminal
insert, four repeats) cDNA cloned into pSG5 [12], and a GSK-3L
cDNA cloned into pMT-2 [8]. Transfected cells were treated with
cytochalasin B at a ¢nal concentration of 20 WM for 1 h and with
LiCl at a range of concentrations of 0.1, 0.5, 1, 5, 10 and 25 mM for
6 h before adding cytochalasin B. Cell survival was estimated after
incubation with propidium iodide (0.6 Wg/ml).
2.2. Antibodies and immunocytochemistry
The B19 rabbit polyclonal antibody [13] recognizes tau in a phos-
phorylation-independent manner. The mouse monoclonal antibodies
AT8 and AT180 (Innogenetics, Belgium), AD2 and 12E8 are speci¢c
for tau phosphorylated on Ser-202/Thr-205 (AT8), Thr-231 (AT180)
[14], Ser-396/404 (AD2) [15], Ser-262/356 (12E8) [16]. The mouse
monoclonal antibodies TPKI (Transduction Laboratories) and
DM1A (Sigma) are speci¢c for GSK-3L and K-tubulin, respectively.
Cells were rinsed in a stabilization bu¡er (PIPES 80 mM, MgCl2
1 mM, EGTA 1 mM, polyethyleneglycol 4% (w/v); pH 6.9) and ¢xed
for 15 min in 4% (w/v) paraformaldehyde in 0.1 M phosphate bu¡er,
pH 7.6. For double immunolabelling, cells were treated for 5 min with
0.01 M Tris, 0.15 M NaCl, pH 7.6, containing 0.3% (w/v) Triton
X-100, then incubated sequentially with the primary antibodies,
with a horse anti-mouse antibody conjugated to biotin (Vector) and
a goat anti-rabbit antibody conjugated to Alexa488 (Molecular
probes), and with streptavidin conjugated to Alexa594 (Molecular
probes).
The number of transfected cells with processes (de¢ned as an out-
growth greater than 10 Wm) was expressed as a percentage of the total
number of transfected cells (100 transfected cells examined). The
length of processes was measured on digital images using the public
domain NIH Image program (version 1.61). Statistical comparisons
were performed using the chi-squared test and the Student t test. Cells
were also ¢xed for 1 h in 4% (v/v) glutaraldehyde, embedded in Epon
and ultrathin sections were examined in electron microscopy.
2.3. Western blotting
For Western blot analysis, cultured cells were homogenized in a
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bu¡er containing proteases and phosphatases inhibitors (Tris 50 mM,
EDTA 10 mM, NaCl 100 mM, pH 7.4, PMSF 1 mM, leupeptin 25 Wg/
ml, pepstatin 25 Wg/ml, Na3VO4 1 mM, Na4P2O7W10H2O 10 mM,
NaF 20 mM) and kept frozen at 320‡C. The amounts of proteins
in homogenates were estimated with the Bradford method (Bio-Rad
reagent). Homogenates were run on 10% (w/v) polyacrylamide gels
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and pro-
teins were electrophoretically transferred to nitrocellulose membrane.
Nitrocellulose membranes were blocked in non-fat milk (10% (w/v) in
TBS) for 1 h at room temperature and incubated with the primary
antibody overnight followed by anti-mouse immunoglobulins conju-
gated to biotin followed by streptavidin conjugated to alkaline phos-
phatase. Membranes were ¢nally incubated in the developing bu¡er
(Tris 0.1 M, NaCl 0.1 M, MgCl2 0.05 M, pH 9.5) containing nitro
blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate. The
amount of tau in every sample was normalized to give a similar
immunoreactivity with the B19 phosphorylation-independent tau anti-
body.
3. Results
3.1. Cytochalasin B-induced processes in tau-transfected cells
Only after treatment with cytochalasin did many tau-trans-
fected CHO cells harbor one or several thin and straight
Fig. 2. Transmission electron microscopy. High magni¢cation showing the density of microtubules and their regular spacing in ultrathin sec-
tions parallel (A) or perpendicular (B) to the long axis of processes in tau-transfected cells. Scale bar: 100 nm.
Fig. 1. Double immunolabelling with the B19 antibody to tau (A) and the DM1A antibody to tubulin (B), on tau-transfected CHO cells treated
with cytochalasin B. Tau-transfected cells exhibit processes that contain microtubule bundles. These bundles are absent in a non-transfected cell
(double arrow in B). Scale bar: 10 Wm.
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processes with a length of 25.2 Wm þ 1.2 Wm (mean þ S.E.M.)
(Fig. 1A,B). These processes contained bundles of microtu-
bules running parallel to their long axis (Fig. 2) and separated
from each other by a regular spacing. 54% þ 0.8% (mean þ
S.E.M.) of tau-transfected cells and only 1.2% of non-trans-
fected cells showed processes (Fig. 2).
3.2. Inhibition of process induction in cells co-transfected with
tau and GSK-3L
The proportion of tau/GSK-3L-co-transfected cells exhibit-
ing a process was less than for tau-transfected cells
(54% þ 0.8% versus 30% þ 1.3% (mean þ S.E.M.) (Figs. 3 and
5A,B). In co-transfected cells, the processes had a length of
25.1 Wm þ 1.3 Wm (mean þ S.E.M.). By immunocytochemistry,
most tau-transfected cells (detected by the B19 antibody) were
also 12E8- (96%), AD2- (80%) and AT180- (59%) positive but
only 10% of them were AT8-positive. This observation was
con¢rmed by immunoblotting analysis : several tau immuno-
reactive species (corresponding to di¡erentially phosphor-
ylated species of a single transfected tau isoform) were
detected both with the B19 phosphorylation-independent anti-
body and the AD2 phosphorylation-dependent tau antibody
in tau-transfected cells (Fig. 4A,B, lanes 2). No tau species
were detected in non-transfected cells (Fig. 4A,B, lanes 1).
Comparison of immunoblots of tau-transfected cells and
tau/GSK-3L-co-transfected cells indicated a decrease in the
electrophoretic mobility of tau bands (Fig. 4A, lane 3) and
an increase in the immunoreactivity of tau bands with the
AD2 phosphorylation-dependent tau antibody species in tau/
GSK-3L-co-transfected cells (Fig. 4B, lane 3). The same shift
in electrophoretic mobility was observed with the 12E8 and
the AT180 antibodies (not shown).
3.3. Lithium reverses the inhibitory e¡ect of GSK-3L on process
induction
The LiCl treatment of tau/GSK-3L-co-transfected cells (Fig.
5C,D) increased the percentage of cells exhibiting processes. A
signi¢cant e¡ect was already observed at a concentration of
0.1 mM of LiCl and the percentage of tau/GSK-3L-co-trans-
fected cells exhibiting processes increased in a dose-dependent
manner (Fig. 6). A minor increase in the percentage of dead
cells was observed in lithium-treated cultures (1.8%, versus
0.6% in untreated cultures). Comparison of immunoblots of
tau/GSK-3L-co-transfected cells treated or not with lithium
showed an increase in the electrophoretic mobility of several
tau bands after lithium treatment (Fig. 4A, lane 4) and a
decrease in the immunoreactivity of the slower migrating
tau bands with the AD2 phosphorylation-dependent tau anti-
body (Fig. 4B, lane 4).
4. Discussion
The induction of cell processes containing microtubule bun-
dles was reported to be enhanced after reorganization of the
actin network by cytochalasin treatment in MAP2c-trans-
fected hepatoma cells [17] and in tau-expressing Sf9 cells
[18]. We similarly observed that cytochalasin treatment of
tau-transfected CHO cells was necessary to induce the forma-
tion of processes. We observed a highly signi¢cant decrease in
the percentage of cells with processes among tau/GSK-3L-co-
transfected cells, indicating that the expression of GSK-3L
Fig. 3. Processes formation in non-transfected (NT), tau-transfected
and tau/GSK-3L-co-transfected cells treated with cytochalasin B, ex-
pressed as a percentage of transfected cells with processes (mean þ
S.E.M.). In non-transfected cells, data are expressed as a percentage
of total cell number. *: P6 0.001 compared with tau-transfected
cells by chi-squared test.
Fig. 4. Immunoblotting analysis of transfected and non-transfected
CHO cells with (A) the B19 polyclonal antibody to tau, and (B) the
AD2 phosphorylation-dependent anti-tau monoclonal antibody.
Lanes 1: non-transfected cells ; lanes 2: tau-transfected cells ; lanes
3: tau- and GSK-3L double-transfected cells ; lanes 4: tau- and
GSK-3L double-transfected cells treated with 25 mM LiCl for 7 h.
Identical lanes in (A) and (B) have similar loading of protein. Bars
on the left indicate the position of molecular weight markers:
97.4 kDa (phosphorylase b), 58.1 kDa (catalase), 39.8 kDa (alcohol
dehydrogenase), 29.0 kDa (carbonic anhydrase).
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interferes with process formation. A role for GSK-3L as a
negative regulator of processes outgrowth was further sug-
gested by the observation that lithium enabled co-transfected
cells to regain an ability to develop cell processes. Lithium
acts as a speci¢c inhibitor of GSK-3L in vitro and in intact
cells [9^11,19]. The inhibition of GSK-3L activity by lithium is
dose-dependent, with a half-maximal e¡ect occurring at 1^2
mM in vitro [19]. We also observed a dose-dependent e¡ect of
lithium on process formation, with a half-maximal e¡ect oc-
curring around a concentration of 1 mM. This cellular test
system relying on a morphological change was relatively sen-
sitive, since a 10 times lower lithium concentration (i.e. 0.1
mM) still signi¢cantly a¡ected process formation.
The mean length of cell processes was not di¡erent between
tau-transfected and tau/GSK-3L-co-transfected cells. This ob-
servation is consistent with GSK-3L acting by reducing the
ability of tau to nucleate microtubule assembly, as reported
in a previous study [20]. A reduction of microtubule nuclea-
tion in tau/GSK-3L-co-transfected cells would be expected to
lead to a decrease in the frequency of cell process formation,
but not to an important reduction of their length.
GSK-3L could also negatively modulates process induction
by decreasing microtubule assembly, since GSK-3L was found
to decrease the pool of tau associated to microtubules and to
reduce microtubule bundling [11,21,22]. A massive change in
tau phosphorylation in cultures co-transfected with tau and
GSK-3L could not be demonstrated since many cells trans-
fected with tau only already contained a pool of phosphory-
lated tau proteins, as observed previously in CHO cells
[12,23,24] and con¢rmed by our immunoblotting analysis. In-
terestingly, the transfected tau was phosphorylated at Ser-262/
356 (as observed with the antibody 12E8), a phosphorylation
reported to be associated to a decrease of tau binding to
microtubules and necessary for extension of cell processes in
Fig. 5. Tau/GSK-3L-co-transfected cultures were treated with cytochalasin B alone (A and B) or with lithium followed by cytochalasin B (C
and D) and double-immunolabelled with the B19 anti-tau (A and C) and anti-GSK-3L (B and D) antibodies. A and B: A tau/GSK-3L-co-
transfected cell (arrow in A and B) does not show process whereas an adjacent cell transfected only with tau (arrowhead in A and B) shows
two processes. C and D: In the presence of lithium, a tau/GSK-3L-co-transfected cell shows a process. Scale bar: 10 Wm.
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Sf9 cells [25]. This suggests that phosphorylation of tau at
some sites in CHO cells might actually favor the extension
of cell processes in tau-transfected CHO cells.
We however observed a decrease in the electrophoretic mo-
bility of tau in tau/GSK-3L-co-transfected cells and an in-
crease of its immunoreactivity with the AD2 phosphoryla-
tion-dependent antibody, suggesting that GSK-3L was able
to increase further the phosphorylation of tau in these trans-
fected cells, in agreement with previous studies on transfected
cells [8,22,24]. Lithium treatment of tau/GSK-3L-co-trans-
fected cells increased the electrophoretic mobility of tau in
tau/GSK-3L-co-transfected cells and decreased its immuno-
reactivity with a phosphorylation-dependent antibody, as re-
ported previously [9^11]. Altogether, these results support the
conclusion that the cellular e¡ects induced by GSK-3L, i.e. a
reduction of cell processes outgrowth, were linked to an in-
creased tau phosphorylation. Further studies will however be
necessary to establish that the phenotypic changes induced by
GSK-3L are only due to a direct action on tau. However, our
observations indicate that the microtubule-dependent, tau-in-
duced process outgrowth can be negatively regulated by GSK-
3L activity.
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Fig. 6. E¡ect of di¡erent concentrations of lithium on processes for-
mation in tau/GSK-3L-co-transfected cells. Results are expressed as
a percentage of tau/GSK-3L-co-transfected cells with processes
(mean þ S.E.M.). *: P6 0.05; **: P6 0.01; ***: P6 0.001 com-
pared with cells not treated with lithium, by Student t test.
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